Lotus Eye Hospital [LOTUSEYE] vs Dr. Agarwal's Eye [DRAGARWQ] Detailed Stock Comparison

Lotus Eye Hospital

NSE
Loading...

Dr. Agarwal's Eye

BSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Lotus Eye Hospital wins in 7 metrics, Dr. Agarwal's Eye wins in 12 metrics, with 0 ties. Dr. Agarwal's Eye appears stronger overall.

View Metrics Details

Vital Metrics Comparison

MetricLotus Eye HospitalDr. Agarwal's EyeBetter
P/E Ratio (TTM)379.1940.35Dr. Agarwal's Eye
Price-to-Book Ratio4.2511.14Lotus Eye Hospital
Debt-to-Equity Ratio5.72158.94Lotus Eye Hospital
PEG Ratio-28.441.81Lotus Eye Hospital
EV/EBITDA73.2520.32Dr. Agarwal's Eye
Profit Margin (TTM)1.32%13.96%Dr. Agarwal's Eye
Operating Margin (TTM)4.86%22.71%Dr. Agarwal's Eye
EBITDA Margin (TTM)4.86%22.71%Dr. Agarwal's Eye
Return on Equity1.23%26.07%Dr. Agarwal's Eye
Return on Assets (TTM)1.06%8.91%Dr. Agarwal's Eye
Free Cash Flow (TTM)$-21.28M$-83.80MLotus Eye Hospital
Dividend YieldN/A0.11%N/A
1-Year Return56.59%4.92%Lotus Eye Hospital
Price-to-Sales Ratio (TTM)5.045.64Lotus Eye Hospital
Enterprise Value$2.54B$26.43BDr. Agarwal's Eye
EV/Revenue Ratio5.056.38Lotus Eye Hospital
Gross Profit Margin (TTM)49.70%77.64%Dr. Agarwal's Eye
Revenue per Share (TTM)$24$881Dr. Agarwal's Eye
Earnings per Share (Diluted)$0.32$123.07Dr. Agarwal's Eye
Beta (Stock Volatility)0.42-0.36Dr. Agarwal's Eye
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends

Lotus Eye Hospital vs Dr. Agarwal's Eye Stock Performance Analysis

Loading Price Chart...

Lotus Eye Hospital
Dr. Agarwal's Eye
Lotus Eye Hospital Stock Overview | Dr. Agarwal's Eye Stock Overview

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Lotus Eye Hospital-1.26%1.79%-7.67%68.44%73.42%73.89%
Dr. Agarwal's Eye-0.31%2.98%9.84%14.47%16.54%-23.53%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Lotus Eye Hospital56.59%53.89%294.60%779.28%583.61%240.36%
Dr. Agarwal's Eye4.92%358.10%1,895.43%3,647.65%6,296.19%14,656.04%

News Based Sentiment: Lotus Eye Hospital vs Dr. Agarwal's Eye

Lotus Eye Hospital

News based Sentiment: MIXED

September presented a mixed picture for Lotus Eye Hospital, with revenue growth and analyst confidence countered by regulatory scrutiny, share price volatility, and concerns about profitability. The contrasting signals make it a cautiously optimistic investment story.

View Lotus Eye Hospital News Sentiment Analysis

Dr. Agarwal's Eye

News based Sentiment: POSITIVE

September was a strong month for Dr. Agarwal's, marked by impressive financial results, a commitment to shareholder returns through a 35% dividend, and increasing institutional investor confidence. Long-term projections from Walletinvestor.com further reinforce a positive investment outlook, suggesting significant potential for future growth.

View Dr. Agarwal's Eye News Sentiment Analysis

Performance & Financial Health Analysis: Lotus Eye Hospital vs Dr. Agarwal's Eye

MetricLOTUSEYEDRAGARWQ
Market Information
Market Cap i₹2.54B₹23.46B
Market Cap CategorySmall capSmall cap
10 Day Avg. Volume i28,2641,476
90 Day Avg. Volume i188,8553,361
Last Close₹121.34₹4,950.65
52 Week Range₹54.99 - ₹139.20₹3,500.00 - ₹7,300.00
% from 52W High-12.83%-32.18%
All-Time High₹139.20 (Sep 03, 2025)₹7,300.00 (Dec 30, 2024)
% from All-Time High-12.83%-32.18%
Growth Metrics
Quarterly Revenue Growth0.05%0.17%
Quarterly Earnings Growth-0.13%0.22%
Financial Health
Profit Margin (TTM) i0.01%0.14%
Operating Margin (TTM) i0.05%0.23%
Return on Equity (TTM) i0.01%0.26%
Debt to Equity (MRQ) i5.72158.94
Cash & Liquidity
Book Value per Share (MRQ)₹28.54₹445.96
Cash per Share (MRQ)₹1.98₹52.76
Operating Cash Flow (TTM) i₹5.77M₹738.70M
Levered Free Cash Flow (TTM) i₹7.39M₹546.50M
Dividends
Last 12-Month Dividend Yield iN/A0.11%
Last 12-Month Dividend i₹0.00₹5.00

Valuation & Enterprise Metrics Analysis: Lotus Eye Hospital vs Dr. Agarwal's Eye

MetricLOTUSEYEDRAGARWQ
Price Ratios
P/E Ratio (TTM) i379.1940.35
Forward P/E iN/A510.88
PEG Ratio i-28.441.81
Price to Sales (TTM) i5.045.64
Price to Book (MRQ) i4.2511.14
Market Capitalization
Market Capitalization i₹2.54B₹23.46B
Enterprise Value i₹2.54B₹26.43B
Enterprise Value Metrics
Enterprise to Revenue i5.056.38
Enterprise to EBITDA i73.2520.32
Risk & Other Metrics
Beta i0.42-0.36
Book Value per Share (MRQ) i₹28.54₹445.96

Financial Statements Comparison: Lotus Eye Hospital vs Dr. Agarwal's Eye

Financial Metrics

Loading Financial Charts...

Revenue

EBITDA

Shareholders Equity

Operating Margin

Free Cash Flow

Long Term Debt

Profit Margin

Current Ratio

Operating Cash Flow

Income Statement (MRQ)

Metric (MRQ)LOTUSEYEDRAGARWQ
Revenue/Sales i₹135.17M₹1.17B
Cost of Goods Sold i₹67.99M₹261.40M
Gross Profit i₹67.18M₹907.80M
Research & Development iN/AN/A
Operating Income (EBIT) i₹6.57M₹265.50M
EBITDA i₹16.64M₹379.30M
Pre-Tax Income i₹7.30M₹231.90M
Income Tax i₹1.85M₹59.30M
Net Income (Profit) i₹5.45M₹172.60M

Balance Sheet & Liquidity Metrics (MRQ)

Metric (MRQ)LOTUSEYEDRAGARWQ
Cash & Equivalents i₹20.11M₹111.60M
Total Current Assets i₹115.70M₹559.40M
Total Current Liabilities i₹74.25M₹869.80M
Long-Term Debt i₹20.27M₹3.06B
Total Shareholders Equity i₹600.00M₹2.10B
Retained Earnings i₹143.09M₹1.99B
Property, Plant & Equipment i₹442.83M₹1.37B

Cash Flow Statement Comparison (MRQ)

Metric (MRQ)LOTUSEYEDRAGARWQ
Operating Cash Flow iN/AN/A
Capital Expenditures iN/AN/A
Free Cash Flow iN/AN/A
Debt Repayment iN/AN/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricLOTUSEYEDRAGARWQ
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Average Daily Volume (10 Day) i28,2641,476
Average Daily Volume (90 Day) i188,8553,361
Shares Outstanding i20.80M4.70M
Float Shares i6.87M1.11M
% Held by Insiders i0.65%0.81%
% Held by Institutions i0.00%0.02%

Dividend Analysis & Yield Comparison: Lotus Eye Hospital vs Dr. Agarwal's Eye

MetricLOTUSEYEDRAGARWQ
Last 12-Month Dividend i₹0.00₹5.00
Last 12-Month Dividend Yield iN/A0.11%
3-Year Avg Annual Dividend i₹0.33₹4.50
3-Year Avg Dividend Yield i0.66%0.12%
3-Year Total Dividends i₹1.00₹13.50
Ex-Dividend DateSep 18, 2023Nov 08, 2024